Flotte Terry CV - American Society of Gene & Cell Therapy

Curriculum Vitae: Terence R. Flotte07/01/96 to 08/06/98: Assistant Professor of Pediatrics and Molecular Genetics and Microbiology,University of Florida, College of Medicine08/06/98 to 06/30/01: Associate Professor of Pediatrics and Molecular Genetics and Microbiology,University of Florida, College of Medicine07/01/96 to 11/03/00 Co-Director, Powell Gene Therapy Center, University of Florida College of MedicineInterim Director, University of Florida Genetics Institute11/04/00 to 08/01/02 Director, Powell Gene Therapy Center, University of Florida College of Medicine11/04/00 to 10/01/02 Director, University of Florida Genetics Institute07/01/02 to 04/14/07 Nemours Eminent Scholar, Professor and Chair, Department of PediatricsProfessor, Department of Pediatrics & Molecular Genetics and MicrobiologyUniversity of Florida, College of Medicine04/15/07 to present Professor and Dean, School of MedicineProfessor, Department of PediatricsProvost and Executive Deputy Chancellor, University of Massachusetts MedicalSchoolSELECTED FACULTY HONORS:Elected Member in the Johns Hopkins Society of ScholarsMassachusetts Society for Medical Research, Investigator Award • 2012Celia and Isaac Haidak Professorship in Medical Education • 2010 - to presentSociety for Pediatric Research E. Mead Johnson Award for Outstanding Scientific Contributions • 2005Permanent Charter member NIH Study Section: Gene Drug Delivery Systems •7/1/04 - 6/30/08National Institute of Health College of CSR Reviewers • 01/2010 - to presentHUMAN GENE THERAPY CLINICAL TRIALS:1. rAAV2-CFTR phase I nasal/bronchial: first-in-humans: Primary PI (first subject enrolled 1995)2. rAAV2-CFTR phase I sinus: co-PI (first subject enrolled 1996)3. rAAV2-AAT phase I intramuscular: first-in-humans: Primary PI (first subject enrolled 2003)4. rAAV1-AAT phase I intramuscular: first-in-humans: Primary PI (first subject enrolled 2006)5. rAAV2-rpe65 phase I subretinal injection: co-PI (first subject enrolled 2007)6. rAAV2-sFLT01 phase I intravitreal injection: co-PI ( first subject enrolled 2010)7. A Randomized Controlled Trial of ProstAtak as Adjuvant to Up-Front Radiation Therapy forLocalized Prostate Cancer (enrollment pending)GRANTS AWARDED (CURRENT)National Institutes of Health (NHLBI) 1-R01-HL69877 (PI: Flotte)"Preclinical & Phase I/II Trials of AAV-AAT Vectors"$250,000/year Direct Cost ($2,039,235 total Direct cost (DC)/In direct cost (IDC)). April 2003 to June2014 (ACTIVE)National Institutes of Health (NHLBI) P01-HL59412 (Project PI: Flotte; PPG Director: Muzyczka)Page 2 of 29